Cannabis and Opioid Substitution

Plain-language summary

This is not medical advice. Talk to a clinician before changing opioid medication. Stopping opioids abruptly can cause serious withdrawal and increases overdose risk if you relapse.

The core question: can cannabis help people take fewer opioids, or quit them entirely? Three different versions of that question have different answers.

1. In chronic pain patients already on opioids, some studies and many patient surveys suggest cannabis can reduce opioid doses Weak / limited. Randomized trial evidence is limited and mixed ^[1][2].
2. As a treatment for opioid use disorder (OUD) — the addiction itself — cannabis is not an established treatment. Methadone, buprenorphine, and naltrexone are Strong evidence^[3].
3. At the population level, an influential 2014 study found medical cannabis states had lower opioid overdose death rates ^[4]. A 2019 reanalysis with more years of data reversed that finding ^[5] Disputed.

What probably works

Medications for opioid use disorder (MOUD) — not cannabis — remain the standard of care. Buprenorphine and methadone substantially reduce overdose death, illicit opioid use, and all-cause mortality in people with OUD Strong evidence^[3][6]. Any discussion of cannabis substitution should start here: if someone has OUD, the proven life-saving treatment is MOUD.

For chronic non-cancer pain, cannabinoids (including THC, nabiximols, and synthetic THC) produce modest reductions in pain scores in meta-analyses Strong evidence^[1]. The effect size is small to moderate and roughly comparable to other adjuncts, not a miracle.

What might work

Opioid-sparing in chronic pain. Observational studies and patient surveys repeatedly find that people using medical cannabis report reducing their opioid use, sometimes substantially ^[2][7] Weak / limited. A 2017 Minnesota program review of intractable pain patients found roughly 38% of those on opioids at baseline had reduced or eliminated them after six months ^[7]. Self-report and selection bias are obvious limitations.

CBD for craving and anxiety in opioid-abstinent individuals. A small 2019 randomized trial by Hurd and colleagues found cannabidiol reduced cue-induced craving and anxiety in people with heroin use disorder ^[8] Weak / limited. Promising but one study, short follow-up, no relapse or overdose endpoints.

Cannabis as an adjunct during opioid tapering. Some clinical programs report patients tolerate tapers better with cannabis available Anecdote. Controlled data are sparse.

What doesn't work or has weak evidence

Cannabis as a stand-alone treatment for OUD. There is no high-quality evidence that cannabis treats opioid addiction itself. Some cohort studies even suggest cannabis use during OUD treatment is associated with worse retention or more illicit opioid use, though findings are inconsistent Disputed^[9].

The population-level overdose death claim. The widely cited Bachhuber 2014 paper ^[4] showed medical cannabis laws were associated with ~25% lower opioid overdose mortality from 1999–2010. Shover et al. (2019) extended the same analysis to 2017 and found the relationship reversed — states with medical cannabis laws had slightly higher overdose mortality ^[5]. This is a textbook example of an ecological correlation that did not hold up Disputed.

"Cannabis is a safer painkiller than opioids, full stop." This is folklore-grade marketing. Cannabis has a much lower acute overdose risk than opioids Strong evidence, but "safer than opioids" is a low bar and ignores risks like cannabis use disorder, cognitive effects, cardiovascular events, and cannabinoid hyperemesis syndrome.

What we don't know

• Whether THC, CBD, or specific ratios drive any opioid-sparing effect. Most trials use whole-plant or nabiximols; component contributions are unclear.
• Whether long-term cannabis substitution improves or worsens functional outcomes (work, mood, sleep) versus careful opioid management.
• Whether cannabis helps or hurts retention in buprenorphine/methadone programs. Studies disagree ^[9].
• Optimal dosing, route (inhaled vs. oral), and duration.
• Effects in older adults, who account for a growing share of both chronic pain and opioid prescriptions.
• Whether early CBD findings for opioid craving ^[8] will replicate in larger trials with hard endpoints.

Comparison with standard treatments

| Use case | Standard of care | Cannabis evidence | |---|---|---| | Opioid use disorder | Buprenorphine, methadone, naltrexone Strong evidence | Insufficient Weak / limited | | Chronic non-cancer pain (opioid-sparing) | Multimodal: PT, non-opioid analgesics, behavioral therapy | Modest opioid-sparing in observational data Weak / limited | | Acute pain | Short-course opioids, NSAIDs, acetaminophen | Limited; not first-line | | Opioid withdrawal | Buprenorphine, methadone, lofexidine, clonidine | Anecdotal; no controlled evidence for symptom control Anecdote |

MOUD reduces all-cause mortality by roughly half in people with OUD ^[6]. No cannabis intervention has demonstrated anything comparable. Substituting cannabis for MOUD in someone with active OUD is not supported by current evidence.

Risks and harms

• Cannabis use disorder. Roughly 10% of users and ~30% of daily users meet criteria for CUD over time Strong evidence^[10]. Trading opioid dependence for cannabis dependence is still a tradeoff.
• Drug interactions. CBD and THC interact with cytochrome P450 enzymes and can alter levels of methadone, benzodiazepines, and other drugs Strong evidence.
• Sedation stacking. Combining cannabis with opioids, benzodiazepines, or alcohol increases sedation and respiratory depression risk, even though cannabis alone rarely causes fatal respiratory depression.
• Mental health. THC can worsen anxiety, psychosis risk in vulnerable individuals, and may complicate co-occurring PTSD or depression in OUD patients.
• Cardiovascular. Acute THC exposure raises heart rate and may increase MI risk in susceptible individuals.
• Legal and employment risk varies by jurisdiction and remains real even in legal-cannabis states for federally regulated workers and pain-contract patients.

See also: Cannabis Use Disorder, Drug Interactions with Cannabis, Chronic Pain and Cannabis.

Bottom line

Cannabis is plausibly useful as an opioid-sparing adjunct for some chronic pain patients, the evidence is genuinely weak but not zero, and it is not a substitute for proven addiction treatment in people with OUD. The early population-level overdose-death story did not survive more data. If you or someone you know is struggling with opioids, the highest-evidence move is buprenorphine or methadone access, not switching to cannabis.

This article is for education. It is not medical advice. Decisions about opioids, OUD treatment, and cannabis should involve a qualified clinician.

Sources

How this page was made

Related

• Cannabis Use Disorder — A real DSM-5 diagnosis affecting roughly 1 in 5 regular users, with modest but growing evi...